Fatty Liver Symptoms

Fatty Liver Symptoms: The Silent Disease and What to Watch For

Non-alcoholic fatty liver disease (NAFLD) affects approximately 25% of the global population, yet most people living with this condition have no idea they have it. This is because fatty liver disease is often called a “silent” disease—one that progresses quietly without obvious warning signs until significant damage has occurred.

Understanding the symptoms of fatty liver disease, recognising associated conditions that increase your risk, and knowing when to seek medical attention can be crucial for preventing progression to more serious liver conditions like cirrhosis and liver cancer.

Why Fatty Liver Disease Is Often Symptomless

The liver is a remarkably resilient organ. It can continue functioning relatively normally even when up to 75% of its tissue is damaged or diseased. This remarkable capacity for compensation means that fatty liver disease can progress silently for years without producing noticeable symptoms.

Studies consistently show that the majority of people with NAFLD are completely asymptomatic and are diagnosed incidentally during routine medical examinations or imaging studies performed for unrelated reasons. In fact, between 48-100% of people with non-alcoholic steatohepatitis (NASH)—the more advanced, inflammatory form of fatty liver disease—have no symptoms at the time of diagnosis.

This silent nature makes fatty liver disease particularly insidious. By the time symptoms appear, significant liver damage may have already occurred.

Early Stage Fatty Liver Symptoms

While most people with early-stage NAFLD experience no symptoms, some individuals may notice subtle signs that are easy to dismiss or attribute to other causes:

Fatigue and Weakness

Fatigue is the most commonly reported symptom among those with fatty liver disease who do experience symptoms. This isn’t just ordinary tiredness—it’s a persistent, overwhelming exhaustion that doesn’t improve with rest. The fatigue associated with liver disease results from the liver’s reduced capacity to perform its metabolic functions efficiently.

Upper Abdominal Discomfort

Some people with fatty liver disease experience a dull, aching sensation or feeling of fullness in the upper right side of the abdomen, where the liver is located. This discomfort typically results from hepatomegaly (liver enlargement) as fat accumulates within the organ. The liver itself doesn’t have pain receptors, but its capsule can stretch as the organ enlarges, causing discomfort.

Non-Specific Digestive Symptoms

Research has identified that gastrointestinal problems are common among NAFLD patients, including:

• Bloating
• General abdominal discomfort
• Changes in bowel habits

These symptoms occur because liver dysfunction affects bile production and overall digestive processes.

Unexplained Weight Fluctuations

While obesity is a major risk factor for fatty liver disease, some people may notice unexplained changes in weight or difficulty losing weight despite diet and exercise efforts. The metabolic dysfunction underlying fatty liver disease can make weight management particularly challenging.

Other Subtle Signs

Studies examining clinical presentations of NAFLD have identified several other symptoms that patients commonly report:

• Increased thirst sensation
• Sleep disorders and daytime sleepiness
• Anxiety
• Warming sensations

It’s important to note that these symptoms are non-specific and can be caused by numerous other conditions. However, if you experience these symptoms alongside risk factors for fatty liver disease, it’s worth discussing with your healthcare provider.

Could underlying gut issues be contributing to your symptoms? Your gut microbiome plays a crucial role in liver health. Understanding your microbiome composition through comprehensive testing can provide insights into potential contributors to both digestive symptoms and metabolic dysfunction.

Discover the reasons for your gut symptoms.

View our gut health tests

Conditions Strongly Associated with Fatty Liver Disease: Important Indicators

One of the most effective ways to identify your risk for fatty liver disease is to recognise the conditions that commonly occur alongside it. NAFLD is considered the hepatic manifestation of metabolic syndrome, and approximately 90% of people with fatty liver disease have at least one component of metabolic syndrome.

Metabolic Syndrome: The Cluster of Conditions

Metabolic syndrome is diagnosed when you have three or more of the following five criteria:

1. Central Obesity: Increased waist circumference (>40 inches for men, >35 inches for women in the US)
2. Elevated Blood Pressure: ≥130/85 mmHg or taking blood pressure medication
3. High Fasting Blood Glucose: ≥100 mg/dL or taking diabetes medication
4. Elevated Triglycerides: ≥150 mg/dL or taking medication for high triglycerides
5. Low HDL Cholesterol: <40 mg/dL for men, <50 mg/dL for women, or taking medication

The relationship between metabolic syndrome and NAFLD is bidirectional—having metabolic syndrome increases your risk of developing fatty liver disease, and having fatty liver disease increases your risk of developing metabolic syndrome components. Studies show that approximately 33% of NAFLD patients meet criteria for full metabolic syndrome, and with each additional metabolic syndrome component, the risk of liver steatosis increases exponentially.

If you have metabolic syndrome, there’s a high probability you also have fatty liver disease, even without symptoms.

Type 2 Diabetes: A Major Red Flag

The association between type 2 diabetes and NAFLD is particularly strong:

• NAFLD prevalence ranges from 28-55% in people with type 2 diabetes
• People with NAFLD have a significantly increased risk of developing type 2 diabetes (adjusted odds ratio of 3.51)
• Diabetic patients with NAFLD tend to have more severe liver inflammation, advanced fibrosis, and increased overall mortality compared to NAFLD patients without diabetes

The relationship is bidirectional and involves complex interactions between insulin resistance, hepatic glucose production, and fat metabolism. If you have type 2 diabetes, your healthcare provider should screen you for fatty liver disease, even in the absence of symptoms.

Obesity and Central Adiposity

Obesity dramatically increases fatty liver disease risk:

• The prevalence of NAFLD exceeds 75% in people with obesity
• NAFLD prevalence is particularly high (51-61%) among individuals with obesity
• However, it’s not just total body weight—visceral adipose tissue (fat around internal organs) is particularly problematic

Visceral fat is metabolically active, releasing inflammatory cytokines and free fatty acids directly into the portal circulation that flows to the liver. Studies show that increased waist circumference is one of the most common metabolic syndrome components in NAFLD patients.

Importantly, “lean NAFLD” can occur in people with normal BMI but increased visceral adiposity, demonstrating that fatty liver disease isn’t exclusively a condition of obesity.

Dyslipidemia: Abnormal Cholesterol and Triglycerides

Lipid abnormalities are extremely common in fatty liver disease:

• Dyslipidemia occurs in 27-92% of NAFLD patients
• Hyperlipidemia affects approximately 69% of people with NAFLD
• Low HDL cholesterol is one of the most frequently observed metabolic abnormalities

The presence of dyslipidemia in NAFLD reflects the liver’s central role in lipid metabolism. When the liver becomes fatty and insulin resistant, it produces excess triglycerides and VLDL particles while HDL cholesterol decreases.

Hypertension: High Blood Pressure

Hypertension is present in approximately 39% of people with NAFLD. The relationship involves complex mechanisms including:

• Insulin resistance enhancing sodium reabsorption
• Increased sympathetic nervous system activity
• Endothelial dysfunction

Having hypertension alongside other metabolic risk factors substantially increases the likelihood of fatty liver disease.

Small Intestinal Bacterial Overgrowth (SIBO)

Emerging research has identified associations between SIBO and fatty liver disease:

• SIBO prevalence in NAFLD patients can reach approximately 35%
• Meta-analyses have found odds ratios ranging from 1.5 to 3.82 for NAFLD among patients with SIBO
• The relationship may involve increased intestinal permeability, bacterial translocation, and nutrient malabsorption

If you experience digestive symptoms like bloating, abdominal discomfort, or irregular bowel movements alongside metabolic concerns, SIBO testing may be warranted.

Wondering if SIBO could be affecting your liver health? Our convenient SIBO breath tests can identify bacterial overgrowth that may be contributing to inflammation and metabolic dysfunction.

Cardiovascular Disease

NAFLD is strongly associated with cardiovascular disease, which represents the leading cause of death in people with fatty liver disease:

• People with NAFLD have a 57-69% increased risk of cardiovascular disease, independent of traditional risk factors
• NAFLD patients show higher rates of coronary heart disease, myocardial infarction, and stroke
• The association appears to be independent of obesity and other metabolic factors

If you have cardiovascular disease or cardiovascular risk factors, fatty liver disease screening is important.

Chronic Kidney Disease (CKD)

Research demonstrates significant associations between NAFLD and kidney disease:

• NAFLD increases both prevalence and incidence of CKD
• NASH is associated with even higher CKD risk than simple steatosis
• CKD prevalence ranges from 16-32% in NAFLD patients compared to 4-22% in those without NAFLD

The shared metabolic dysfunction, oxidative stress, and inflammation likely link these two conditions.

Advanced Fatty Liver Symptoms: When NASH Progresses to Cirrhosis

As fatty liver disease advances from simple steatosis to NASH and potentially to cirrhosis, more severe symptoms can develop. However, it’s crucial to understand that even advanced liver disease can initially be “compensated,” meaning the liver still functions adequately despite significant scarring.

Compensated Cirrhosis

In the compensated stage of cirrhosis, many people still have no symptoms or only mild, non-specific symptoms like fatigue. However, some may notice:

• Increased fatigue and weakness
• Loss of appetite
• Unexplained weight loss
• Mild nausea
• Difficulty concentrating or mild confusion

Decompensated Cirrhosis: Serious Warning Signs

When cirrhosis becomes “decompensated,” the liver can no longer compensate for the damage, and serious complications develop. Decompensated cirrhosis is characterised by one or more major complications:

1. Ascites (Fluid Accumulation in the Abdomen)

Ascites is the most common complication of cirrhosis, affecting approximately 60% of people with cirrhosis within 10 years of diagnosis. Symptoms include:

• Progressive abdominal swelling and distention
• Rapid weight gain (from fluid, not fat)
• Difficulty breathing (when fluid presses on the diaphragm)
• Abdominal discomfort or pain
• Feeling of fullness even after small meals
• Swelling in the legs and ankles (peripheral oedema)

2. Jaundice (Yellowing of Skin and Eyes)

Jaundice occurs when the damaged liver cannot adequately process bilirubin, a yellow pigment produced from the breakdown of red blood cells. Signs include:

• Yellow discolouration of the skin
• Yellowing of the whites of the eyes (sclera)
• Dark, tea-coloured urine
• Pale or clay-coloured stools

3. Hepatic Encephalopathy (Brain Dysfunction)

When the damaged liver cannot filter toxins from the blood, these substances can affect brain function, causing:

• Confusion and disorientation
• Memory problems
• Difficulty concentrating
• Personality changes
• Sleep disturbances (sleeping during the day, awake at night)
• Slurred speech
• Difficulty with coordination and movement
• In severe cases, coma

Studies show that hepatic encephalopathy develops at a rate of approximately 2.39 per 100 persons per year in those with cirrhosis.

4. Variceal Bleeding

Portal hypertension (increased blood pressure in the portal vein) causes blood to be rerouted through smaller veins in the esophagus and stomach. These veins can become enlarged (varices) and rupture, causing:

• Vomiting blood (which may be bright red or look like coffee grounds)
• Black, tarry stools (melena)
• Bloody stools
• Lightheadedness or fainting
• Signs of shock in severe cases

Variceal bleeding occurs at a rate of approximately 0.70 per 100 persons per year in cirrhosis patients and requires emergency medical treatment.

5. Easy Bruising and Bleeding

The damaged liver produces inadequate amounts of clotting factors, leading to:

• Easy bruising from minor bumps
• Prolonged bleeding from cuts
• Frequent nosebleeds
• Bleeding gums
• Small red or purple spots on the skin (petechiae)

6. Severe Itching (Pruritus)

Accumulation of bile salts in the skin can cause intense, persistent itching that’s often worse at night and can significantly impact quality of life.

7. Spider Angiomas and Palmar Erythema

Visible changes in the skin include:

• Spider-like blood vessels just beneath the skin’s surface (spider angiomas), typically on the upper body
• Redness of the palms (palmar erythema)

8. Gynecomastia and Testicular Atrophy

Hormonal changes in men with cirrhosis can cause:

• Breast tissue development (gynecomastia)
• Testicular shrinkage
• Loss of body hair
• Reduced libido

Hepatocellular Carcinoma (Liver Cancer)

People with NASH and cirrhosis are at increased risk of developing hepatocellular carcinoma (HCC), the most common type of primary liver cancer. HCC may not cause symptoms in early stages but can eventually lead to:

• Unexplained weight loss
• Loss of appetite
• Upper abdominal pain
• Nausea and vomiting
• General weakness and fatigue
• Abdominal swelling
• Jaundice

Studies show HCC develops at a rate of approximately 0.14 per 100 persons per year in those with cirrhosis, though this rate may be higher in certain populations.

The Importance of Screening When You Have Risk Factors

Given that fatty liver disease is typically asymptomatic in its early stages, proactive screening becomes crucial for at-risk individuals. The goal of screening is to:

1. Identify the disease before significant damage occurs
2. Implement interventions to prevent progression
3. Monitor for development of complications
4. Reduce the risk of liver-related morbidity and mortality

Who Should Be Screened?

Current evidence suggests screening should be considered for individuals with:

• Type 2 diabetes
• Obesity or overweight status (especially with central adiposity)
• Metabolic syndrome or any of its components
• Persistently elevated liver enzymes (ALT, AST) without other explanation
• Dyslipidemia
• Hypertension
• Polycystic ovary syndrome (PCOS)
• Sleep apnea
• Family history of NAFLD or NASH
• Long term digestive symptoms that could indicate gut dysbiosis or SIBO

How Is Fatty Liver Disease Diagnosed?

Diagnosis typically involves:

Blood Tests: Liver function tests (ALT, AST, GGT, alkaline phosphatase, bilirubin, albumin) can indicate liver damage, though normal enzymes don’t exclude NAFLD.

Imaging Studies:

• Ultrasound (most common initial test)
• CT scan
• MRI and MRI-PDFF (most accurate for quantifying liver fat)
• FibroScan (transient elastography) to assess both steatosis and fibrosis

Non-Invasive Fibrosis Tests: Various blood-based scores and imaging techniques can estimate the degree of liver scarring without biopsy.

Liver Biopsy: Remains the gold standard for diagnosing NASH and accurately staging fibrosis, though it’s invasive and typically reserved for cases where diagnosis is unclear or advanced disease is suspected.

Discover the reasons for your gut symptoms.

View our gut health tests

Taking Action: What You Can Do Today

If you have risk factors for fatty liver disease or any of the associated conditions discussed in this article, taking proactive steps is essential:

1. Get Screened

Don’t wait for symptoms to appear. If you have metabolic syndrome components, type 2 diabetes, obesity, or other risk factors, talk to your healthcare provider about screening for fatty liver disease.

2. Assess Your Gut Health

The gut-liver axis plays a critical role in fatty liver disease development and progression. Understanding your gut microbiome composition can reveal imbalances that may be contributing to metabolic dysfunction and liver inflammation.

Ready to understand how your gut health might be affecting your liver? Our comprehensive microbiome testing identifies bacterial imbalances, diversity issues, and pathogenic strains associated with fatty liver disease and metabolic dysfunction.

3. Test for SIBO

If you experience digestive symptoms alongside metabolic concerns, SIBO could be a contributing factor to your liver health issues.

Concerned about SIBO? Our at-home breath test kits provide accurate assessment of small intestinal bacterial overgrowth, helping you and your healthcare provider develop targeted treatment strategies.

4. Address Metabolic Risk Factors

Work with your healthcare team to optimise:

• Blood sugar control
• Blood pressure
• Cholesterol and triglyceride levels
• Body weight (even 5-10% weight loss can significantly improve liver fat and inflammation)

5. Optimise Your Lifestyle

Evidence-based interventions include:

Diet: Follow a Mediterranean-style diet rich in vegetables, fruits, whole grains, lean proteins, and healthy fats. Limit refined carbohydrates, added sugars (especially fructose), saturated fats, and processed foods.

Exercise: Aim for at least 150 minutes of moderate-intensity aerobic activity weekly, plus resistance training. Physical activity improves insulin sensitivity and reduces liver fat, even without significant weight loss.

Sleep: Prioritise adequate, quality sleep. Sleep disorders are common in NAFLD patients and can worsen metabolic dysfunction.

Avoid Hepatotoxins: Limit alcohol consumption completely if you have fatty liver disease, and avoid unnecessary medications that can stress the liver.

6. Consider Targeted Supplementation

While lifestyle modifications remain the cornerstone of treatment, certain supplements may support liver and metabolic health:

Support your liver health from the inside out. Our science-backed supplements include probiotics formulated to promote beneficial gut bacteria, prebiotics to support microbiome health, and targeted nutrients that support both liver function and metabolic health. Omega-3 fatty acids, vitamin E (in appropriate cases), and specific probiotic strains have shown promise in research studies for supporting liver health.

7. Monitor Regularly

If you’ve been diagnosed with fatty liver disease, regular follow-up with your healthcare provider is essential. Monitoring typically includes:

• Periodic blood tests to assess liver function
• Imaging studies to evaluate liver fat and potential fibrosis progression
• Screening for complications in advanced disease
• Assessment of metabolic parameters

The Silent Progression: Why Early Detection Matters

Fatty liver disease progresses through distinct stages:

1. Simple Steatosis (Fatty Liver): Fat accumulation without significant inflammation—relatively benign if addressed early
2. NASH (Non-Alcoholic Steatohepatitis): Fat accumulation plus inflammation and liver cell damage
3. Fibrosis: Progressive scarring of liver tissue
4. Cirrhosis: Severe, often irreversible scarring that significantly impairs liver function
5. End-Stage Liver Disease: Liver failure, often requiring transplantation

The transition from steatosis to cirrhosis can take years to decades, but progression is highly variable among individuals. Studies show that approximately 20% of people with NASH develop cirrhosis, and once cirrhosis develops, the risk of complications and mortality increases substantially.

The key insight: The earlier fatty liver disease is detected and addressed, the better the outcomes. Simple steatosis is often reversible with lifestyle modifications. NASH can sometimes be reversed or stabilised. But once significant fibrosis or cirrhosis develops, the damage becomes much harder to reverse, though progression can often still be slowed.

Conclusion: Listen to Your Body and Know Your Risk

Fatty liver disease is called a silent disease for good reason—most people with this condition experience no symptoms until significant damage has occurred. However, this doesn’t mean you’re powerless. By understanding the conditions strongly associated with fatty liver disease, recognising subtle early symptoms, and taking proactive steps toward screening and lifestyle optimisation, you can identify and address this condition before it progresses to more serious stages.

The most important takeaway: If you have metabolic syndrome, type 2 diabetes, obesity, hypertension, dyslipidemia, or digestive issues, you’re at high risk for fatty liver disease, even without symptoms. Don’t wait for symptoms to appear—they may not emerge until the disease is advanced.

Taking action today—through comprehensive health screening, gut microbiome assessment, metabolic optimisation, and evidence-based lifestyle modifications—can make the difference between reversing early fatty liver disease and facing the serious complications of cirrhosis and liver failure years down the line.

Your liver and gut health are intimately connected. Understanding your unique microbiome composition, addressing potential SIBO, managing metabolic risk factors, and supporting your body with targeted interventions gives you the best chance of maintaining optimal liver health for years to come.

Ready to take control of your liver health? Start with understanding your gut. Comprehensive microbiome testing and SIBO assessment provide the foundation for personalised interventions that address the root causes of metabolic dysfunction and support optimal liver health.

---

References

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. https://pubmed.ncbi.nlm.nih.gov/28714183/
2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. https://pubmed.ncbi.nlm.nih.gov/26707365/
3. Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood). 2015;240(6):809-820. https://pubmed.ncbi.nlm.nih.gov/25873078/
4. Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63. https://pubmed.ncbi.nlm.nih.gov/35287643/
5. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 2007;22(6):788-793. https://pubmed.ncbi.nlm.nih.gov/17565631/
6. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1. https://pubmed.ncbi.nlm.nih.gov/32044314/
7. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver disease, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917-923. https://pubmed.ncbi.nlm.nih.gov/12668987/
8. Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936-944. https://pubmed.ncbi.nlm.nih.gov/26667191/
9. Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019;92:82-97. https://pubmed.ncbi.nlm.nih.gov/30502373/
10. Gluvic Z, Sudar-Milovanovic E, Zaric B, et al. Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today? Arch Med Sci. 2022;18(4):1039-1051. https://www.archivesofmedicalscience.com/Non-alcoholic-fatty-liver-disease-metabolic-syndrome-and-type-2-diabetes-mellitus,150639,0,2.html
11. Polyzos SA, Kountouras J, Mantzoros CS. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12:60. https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-020-00570-y
12. Gkouvatsos K, Athyros V, Chatzigeorgiou A, Karagiannis A. The Link between NAFLD and Metabolic Syndrome. Diagnostics (Basel). 2023;13(4):614. https://www.mdpi.com/2075-4418/13/4/614
13. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589-600. https://pubmed.ncbi.nlm.nih.gov/27245905/
14. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71(1):156-162. https://pubmed.ncbi.nlm.nih.gov/33158877/
15. Bang KB, Cho YK. Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med. 2015;5(1):7-13. https://pmc.ncbi.nlm.nih.gov/articles/PMC4608226/
16. Wijarnpreecha K, Lou S, Watthanasuntorn K, et al. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2020;32(5):601-608. https://pubmed.ncbi.nlm.nih.gov/31567712/
17. Gudan A, Jamioł-Milc D, Hawryłkowicz V, Skonieczna-Żydecka K, Stachowska E. The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression. Nutrients. 2022;14(24):5261. https://www.mdpi.com/2072-6643/14/24/5261
18. Sanyal AJ, Van Natta ML, Clark J, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2021;385(17):1559-1569. https://pubmed.ncbi.nlm.nih.gov/34670043/
19. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643-654.e9. https://pubmed.ncbi.nlm.nih.gov/24768810/
20. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. https://pubmed.ncbi.nlm.nih.gov/29653741/